Effects of subcutaneous injections of a long acting moxidectin formulation in grazing beef cattle on parasite fecal egg reduction and animal weight gain.
Trials were conducted in Arkansas, Idaho, Illinois and Wisconsin using a common protocol to evaluate effectiveness and safety of a long acting (LA), oil-based injectable formulation of moxidectin in beef cattle grazing spring and/or summer pastures. At each site, 150 cattle (steers and/or heifers) were blocked based on pretreatment fecal strongyle egg counts (EPG) and then randomly assigned to treatments within blocks. Presence of naturally acquired parasitic infections, confirmed by presence of parasite eggs in feces, was a prerequisite for study enrollment. Within each block of three animals, two received moxidectin LA injectable on day 0 at a dosing rate of 1.0 mg moxidectin/kg b.w. into the dorsal aspect of the proximal third of the ear, and one received a placebo control treatment. Cattle were weighed before treatment and on day 55 or 56 (55/56) after treatment. Fecal samples were also collected from 10 randomly selected blocks of animals at each site on days 14, 28 and 55/56 for EPG quantification. Average daily gain (ADG) was computed over the posttreatment period. Data pertaining to ADG and EPG were combined across sites and analyzed by mixed model analysis of variance to assess the fixed effect of treatment and random effects of site, block within site and the treatment by site interaction. Compared to placebo-treated controls, the geometric means of fecal EPG counts from cattle treated with moxidectin LA injectable were reduced 99.8% 14 days after treatment, 99.1% 28 days after treatment and 96.7% 55/56 days after treatment. Rate of weight gain by cattle treated with moxidectin LA injectable was 0.59 kg/day, or 23% (0.11 kg/day) more than placebo-treated controls (P<0.05). None of the cattle treated with moxidectin LA injectable exhibited signs of macrocyclic lactone toxicosis. Summarized across all study sites, proportions of cattle that received concurrent therapeutic treatments were similar among treatment groups. Study results demonstrate that moxidectin cattle LA injectable administered at a dosing rate of 1.0 mg moxidectin/kg b.w. to grazing beef cattle was effective and safe.
Cleale
R M
RM
Fort Dodge Animal Health, P.O. Box 5366, Princeton, NJ 08543, USA. clealer@pt.fdah.com
Hart
K B
KB
Hutchens
D E
DE
Johnson
E G
EG
Paul
A J
AJ
Smith
L L
LL
Tucker
C
C
Yazwinski
T A
TA
Doscher
M E
ME
Grubbs
S T
ST
Wulster-Radcliffe
M
M
Amodie
D M
DM
D000704:Analysis of Variance; D000818:Animals; D000969:Antinematodal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001131:Arkansas; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000469:parasitology / Q000517:prevention & control; D003692:Delayed-Action Preparations; D005243:Feces / Q000469:parasitology; D005260:Female; D007061:Idaho; D007087:Illinois; D007279:Injections, Subcutaneous / Q000662:veterinary; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D010270:Parasite Egg Count / Q000662:veterinary; D011897:Random Allocation; D012449:Safety; D017206:Strongylida Infections / Q000188:drug therapy / Q000517:prevention & control / Q000662:veterinary*; D016896:Treatment Outcome; D015430:Weight Gain; D014922:Wisconsin
D000969:Antinematodal Agents; D003692:Delayed-Action Preparations; D018942:Macrolides; C027837:moxidectin